A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer.

Trial Profile

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Orteronel (Primary) ; Bicalutamide; LHRH receptor agonists
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 31 Jan 2017 Planned primary completion date changed from 1 Jul 2020 to 1 Mar 2022.
    • 04 Oct 2016 Planned number of patients changed from 1486 to 1304.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top